For the agreement, which extends a previous collaboration between the two groups, the LUMC bought from Bruker four mass spectrometry systems and certain clinical proteomics sample preparation tools and bioinformatics platforms.
LUMC said it will "provide feedback" to Bruker Daltonics on the instrumentation, methods, and software development for clinical research.
Specifically, LUMC's glyco-proteomics group has bought from Bruker an esquire HCT ion trap mass spectrometer for glycan analysis. Additionally, another HCT ion trap will be used for "proteomics work in general," LUMC said.
"We have had a high degree of success with our Ultraflex TOF/TOF mass spectrometer, and are now adding a second one," the lab said in a statement. It will be installing an Apex-Q 9.4 Tesla hybrid Q-q-FTMS system with the ESI/MALDI Combisource, and an ECD/IRMPD accessory for post-translational modification studies. The lab said it will use the APEX-Q and the second Ultraflex TOF/TOF for clinical proteomics and glycoprotein research.
Rob Tollenaar, principal investigator in LUMC's department of surgery's translational research project, said his team will use the mass-spec tools "within the framework of our ... diagnostic and prognostic biomarker research program for the analysis of serum and tissue samples." His lab's research is focused on the improvement of surgical cancer treatment, especially for colorectal, breast, and gastric cancer, as well as cancer diagnosis.